01—Abstract
Summary
Summary of the 10-Q filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson reported strong revenue growth for the nine months ended September 27, 2026, with worldwide sales reaching $74.8 billiona, a 7.4% increase year-over-year.
This growth was driven by both the Innovative Medicine and MedTech segments, with operational increases of 7.4% and 3.5% respectively. The company's net earnings for the nine months, however, significantly decreased to $10.979 billionb from $21.688 billion in the prior year, largely impacted by a substantial $5.5 billion accrual for the proposed resolution of talc ovarian litigation in the third quarter of 2026, which also significantly lowered the effective tax rate. Despite the lower net earnings, the company generated strong operating cash flows of $18.9 billion for the nine months.
The balance sheet remains robust with total assets of $197.4 billionc, although it saw a slight decrease from the prior year. Management highlighted ongoing restructuring initiatives within the MedTech segment and the planned separation of its Orthopaedics business, expected by mid-2027, as key strategic priorities. The company continues to face significant litigation, particularly the talc litigation, which has a material impact on its financial results and disclosures.
02—Key points
Key Highlights
- Worldwide sales increased by 7.4% to $74.8 billion for the nine months ended September 27, 2026, driven by robust performance in both Innovative Medicine and MedTech segments.
- Net earnings for the nine months decreased significantly to $10.979 billion from $21.688 billion in the prior year, primarily due to a $5.5 billion accrual for talc ovarian litigation.
- The Innovative Medicine segment saw strong operational sales growth of 7.4%, with significant contributions from Oncology and Neuroscience products, though Immunology experienced a decline.
- MedTech segment sales grew by 3.5% operationally, with positive contributions from Cardiovascular and Vision, while Surgery and Orthopaedics showed more modest growth.
- Operating cash flow remained strong at $18.9 billion for the nine months, indicating healthy cash generation from ongoing operations.
- The company is undergoing significant restructuring and plans to separate its Orthopaedics business by mid-2027.
- The talc litigation remains a material factor, with a $5.5 billion accrual impacting current period results and ongoing legal proceedings and risks.
03—Questions
Frequently Asked Questions
What was the primary driver for the significant decrease in net earnings for the nine months ended September 27, 2026?
The primary driver for the significant decrease in net earnings was a $5.5 billion accrual recorded in the third quarter of 2026 for the proposed resolution of talc ovarian litigation. This charge, along with other factors like increased R&D expenses, significantly impacted the bottom line compared to the prior year's results.
How did the company's revenue performance vary between its segments (Innovative Medicine and MedTech)?
The Innovative Medicine segment demonstrated strong operational sales growth of 7.4% for the nine months ended September 27, 2026, driven by key products in Oncology and Neuroscience. The MedTech segment also saw positive operational growth of 3.5%, with contributions from Cardiovascular and Vision franchises, though Surgery and Orthopaedics showed slower growth. Overall sales growth was 7.4% worldwide.
What is the status and potential impact of the talc litigation on Johnson & Johnson?
The talc litigation remains a significant concern. Johnson & Johnson has accrued $9.0 billion for talc-related matters as of September 27, 2026, which includes a $5.5 billion commitment for the proposed ovarian cancer litigation settlement. This litigation has a material impact on the company's financial results, including a significant charge impacting net earnings and tax rates. While the company believes it has strong legal grounds, the ongoing nature of the litigation presents ongoing financial and operational risks.
What strategic initiatives are underway, and how might they affect the company's structure and future performance?
Johnson & Johnson is actively engaged in restructuring programs within its MedTech segment and has announced its intention to separate its Orthopaedics business, with the separation expected by mid-2027. These initiatives are aimed at streamlining operations and focusing resources. The separation of the Orthopaedics business will lead to a significant change in the company's structure and could impact its future financial performance and strategic direction.
04—Continue